Cargando…
The Potential Cardiotoxicity of Immune Checkpoint Inhibitors
The use of immune checkpoint inhibitors (ICIs) as a mono- or adjuvant oncologic treatment is rapidly expanding to most fields of cancer. Alongside their efficacy, ICIs carry the risk of immune-related adverse events (irAEs) arising from misguided immune-mediated response to normal tissues. In the ca...
Autores principales: | Nardi Agmon, Inbar, Itzhaki Ben Zadok, Osnat, Kornowski, Ran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836470/ https://www.ncbi.nlm.nih.gov/pubmed/35160316 http://dx.doi.org/10.3390/jcm11030865 |
Ejemplares similares
-
Anti-immunoglobulin-like transcript 3 induced acute myocarditis—A case report
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2022) -
Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2019) -
Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017) -
Cardiomyopathy associated with Ceutzfeld–Jakob disease: a diagnosis of exclusion: a case report
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2020) -
Immune Checkpoint Inhibitors Related to Cardiotoxicity
por: Chen, Ru, et al.
Publicado: (2022)